Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.

Saved in:
Bibliographic Details
Title: Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Authors: O'Brien MP; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Forleo-Neto E; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Sarkar N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Isa F; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Hou P; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Chan KC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Musser BJ; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Bar KJ; Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Microbiology, University of Pennsylvania, Philadelphia, PA, USA., Barnabas RV; Department of Global Health, University of Washington, Seattle, WA, USA; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA; Department of Epidemiology, University of Washington, Seattle, WA, USA; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Barouch DH; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Cohen MS; Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA., Hurt CB; Institute for Global Health and Infectious Diseases, University of North Carolina, Chapel Hill, NC, USA., Burwen DR; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Marovich MA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Brown ER; Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Biostatistics, University of Washington, Seattle, WA, USA., Heirman I; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Davis JD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Turner KC; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Ramesh D; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Mahmood A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Hooper AT; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Hamilton JD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kim Y; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Purcell LA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Baum A; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Kyratsous CA; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Krainson J; Clinical Trials of Florida, LLC, Miami, FL, USA., Perez-Perez R; Medical Research of Westchester, Miami, FL, USA., Mohseni R; Catalina Research Institute, LLC, Montclair, CA, USA., Kowal B; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., DiCioccio AT; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Stahl N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Lipsich L; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Braunstein N; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Herman G; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Yancopoulos GD; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA., Weinreich DM; Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
Corporate Authors: COVID-19 Phase 3 Prevention Trial Team
Source: MedRxiv : the preprint server for health sciences [medRxiv] 2021 Sep 18. Date of Electronic Publication: 2021 Sep 18.
Publication Type: Preprint; Journal Article
Journal Info: Country of Publication: United States NLM ID: 101767986 Publication Model: Electronic Cited Medium: Internet NLM ISO Abbreviation: medRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
DOI:10.1101/2021.06.14.21258569